Navigation Links
Bacchus Vascular Names Scott Cramer as President and CEO
Date:10/16/2007

Experienced Sales Executive to Lead Growing Medical Device Firm

SANTA CLARA, Calif., Oct. 16 /PRNewswire/ -- Bacchus Vascular Inc., a leading provider of innovative medical devices used by interventional radiologists and vascular surgeons for the minimally invasive treatment of deep vein thrombosis (DVT) and other peripheral vascular disease, announced today that it has named Scott Cramer to the position of President and Chief Executive Officer.

Mr. Cramer joined Bacchus Vascular earlier this year as Senior Vice President of Sales. Previously he served as Senior Vice President of U.S. Sales and Account Services for VNUS Medical Technologies (Nasdaq: VNUS) from 2000 until April, 2007. Prior to that, Mr. Cramer held senior management positions with EndoSonics Corporation and Cardiometrics, Inc., as well as management positions with Baxter Healthcare Corporation's cardiovascular division. Mr. Cramer holds a B.S. degree in Finance from the Philadelphia University.

"Scott Cramer has a broad background in the vascular disease and interventional field, a strong track record of introducing innovative medical technologies, and proven success developing new markets," said Elizabeth H. (Bess) Weatherman, Managing Director, Healthcare - Medical Devices for Warburg Pincus LLC, and a Director of Bacchus Vascular.

"Scott brings a wealth of experience to Bacchus Vascular, and we look forward to his leadership in the next phase of the Company's growth," added Thomas Fogarty, MD, Chairman of the Board of Bacchus Vascular.

The Company's previous President and CEO, R. Scott Rader, is relocating to the east coast to fulfill family obligations and pursue other business opportunities. He will remain on the Board of Directors of Bacchus Vascular.

"Scott Rader successfully led Bacchus Vascular through three years of product development, market introduction and clinical success with the Trellis device. We are grateful for his skilled leadership during this stage of the Company's development and are pleased that he will be remaining on the Board of Directors," said Dr. Fogarty.

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately-held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit http://www.bacchusvascular.com.


'/>"/>
SOURCE Bacchus Vascular Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. “Don’t fear long haul flights!” Vascular surgeon tells travelrs
2. People who fight wars may be at high risk of cardiovascular disease
3. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
4. High iron levels may cause Cardiovascular Disease in women
5. Erectile dysfunction (ED) signals vascular disease
6. Drug Effective for Vascular Dementia
7. Air Pollution said To Increase Risk of Cardiovascular Disease
8. Link Between Alcohol Consumption And Cardiovascular Disease
9. Beer Found To Be Effective In Fighting Cardiovascular Disease
10. New Guidelines Found To Benefit Cardiovascular Treatment
11. Women With A High-Risk Of Cardiovascular Disease Under treated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: